|68.48||+0.5300||+0.78%||Vol 6.98M||1Y Perf -33.21%|
|Dec 1st, 2023 16:00 DELAYED|
|- -||0.02 0.03%|
|Target Price||117.25||Analyst Rating||Moderate Buy 1.60|
|Potential %||71.22||Finscreener Ranking||★ 40.97|
|Insiders Trans % 3/6/12 mo.||-100/-89/-79||Value Ranking||★ 39.01|
|Insiders Value % 3/6/12 mo.||-100/-99/-98||Growth Ranking||★+ 42.32|
|Insiders Shares Cnt. % 3/6/12 mo.||-100/-99/-98||Income Ranking||★ 30.45|
|Price Range Ratio 52W %||10.07||Earnings Rating||Sell|
|Market Cap||88.13B||Earnings Date||1st Nov 2023|
Today's Price Range
5 Year PE Ratio Range
|Moving Averages:||Strong Sell|
|Earnings History||Estimate||Reported||Surprise %|
|Earnings Per End||Estimate||Revision %||Trend|
|Next Report Date||-|
|Estimated EPS Next Report||2.13|
|EPS Growth Next 5 Years %||4.50|
|Avg. Weekly Volume||6.65M|
|Avg. Monthly Volume||6.94M|
|Avg. Quarterly Volume||7.10M|
CVS Health Corporation (NYSE: CVS) stock closed at 68.48 per share at the end of the most recent trading day (a 0.78% change compared to the prior day closing price) with a volume of 6.98M shares and market capitalization of 88.13B. Is a component of S&P 500, Russell 1000 indices and it is traded on NYSE exchange. The company belongs in the Healthcare Plans industry, Healthcare sector and employs 300000 people. CVS Health Corporation CEO is Karen S. Lynch.
The one-year performance of CVS Health Corporation stock is -33.21%, while year-to-date (YTD) performance is -26.52%. CVS stock has a five-year performance of -14.61%. Its 52-week range is between 64.41 and 104.83, which gives CVS stock a 52-week price range ratio of 10.07%
CVS Health Corporation currently has a PE ratio of 39.10, a price-to-book (PB) ratio of 1.70, a price-to-sale (PS) ratio of 0.50, a price to cashflow ratio of 5.50, a PEG ratio of 8.69, a ROA of 1.47%, a ROC of 3.37% and a ROE of 4.72%. The company’s profit margin is 0.78%, its EBITDA margin is 3.40%, and its revenue ttm is $238.62 Billion , which makes it $181.60 revenue per share.
Of the last four earnings reports from CVS Health Corporation, there were 4 positive earnings surprise and 0 negative earnings surprise. The company has EPS estimate of $2.13 for the next earnings report. CVS Health Corporation’s next earnings report date is -.
The consensus rating of Wall Street analysts for CVS Health Corporation is Moderate Buy (1.6), with a target price of $117.25, which is +71.22% compared to the current price. The earnings rating for CVS Health Corporation stock is Sell (calculated from actual period earnings estimates revision (80% weight) and previous period earnings surprise (20% weight)).
CVS Health Corporation has a dividend yield of 2.65% with a dividend per share of $2.42 and a payout ratio of 35.00%.
CVS Health Corporation has a Sell technical analysis rating based on Technical Indicators (ADX : 8.38, ATR14 : 1.42, CCI20 : -44.96, Chaikin Money Flow : 0.06, MACD : -0.30, Money Flow Index : 53.70, ROC : 1.00, RSI : 48.64, STOCH (14,3) : 67.53, STOCH RSI : 0.69, UO : 57.59, Williams %R : -32.48), Simple Moving Averages and Exponential Moving Averages.
Aggregated Insider Trades of CVS Health Corporation in the last 12-months were: Karen S. Lynch (Buy at a value of $976 500), Ludwig Edward (Buy at a value of $140 940), Thomas M. Moriarty (Option Excercise at a value of $10 151 220), Thomas M. Moriarty (Sold 137 466 shares of value $13 521 179 )
Mon, 20 Nov 2023 13:21 GMT Analysts Offer Insights on Healthcare Companies: CVS Health (CVS), UnitedHealth (UNH) and Accuray (ARAY)- TipRanks. All rights reserved.
Fri, 08 Sep 2023 06:26 GMT CVS Health (CVS) Receives a Buy from Mizuho Securities- TipRanks. All rights reserved.
Mon, 07 Aug 2023 07:20 GMT Analysts Offer Insights on Healthcare Companies: CVS Health (CVS) and Gilead Sciences (GILD)- TipRanks. All rights reserved.
Copyright © 2016-2023 Finscreener.org. All Rights Reserved.
Disclaimer: Before deciding to trade you should carefully consider your investment objectives, level of experience and your risk appetite. Forex data is a real-time with a 30 second refresh. Prices may not be accurate and may differ from the actual market price. Prices on the website are indicative and solely for informational purposes, not for trading purposes or advice. Please be aware of the risks associated with trading the on financial markets, it is one of the riskiest investment forms. Past performance does not guarantee future profits. We take no responsibility for any losses that may arise as a result of the data contained on this website. The content and the website are provided "as is", without any warranties. In no event will Finscreener.org, its employees, owners, directors, affiliates, partners, data provider, third party or anyone else liable to anyone else for any decision made regarding information on this website.
General partner of Finscreener is SLOVAKODATA, a.s.
This could take some time, please wait.